Drug intelligence / Profile preview

XL-003

Development stage: Preclinical
Lead developer: Allogenica
Modality: Cell Therapies

Overview

XL-003 is a novel engineered pre-T cell therapy under preclinical development by Allogenica SAS. It is being investigated for its potential in treating solid tumors. As a pre-T cell therapy, it represents an advanced form of cell therapy designed to target and eliminate cancer cells. The specific mechanism of action involves engineering T-cell precursors to recognize and attack tumor cells, although the precise target antigen has not been disclosed in the available information.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on XL-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL-003.

Explore the full profile